Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07165938

Genetics of Neonatal Encephalopathy and Related Disorders

Investigators at Boston Children's Hospital are conducting research in order to better understand the genetic factors which may contribute to neonatal encephalopathy (NE) and related disorders. These findings may help explain the broad spectrum of clinical features and outcomes seen in individuals with a history of NE.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Boston Children's Hospital

Boston, Massachusetts, 02115, United States

Location status: Recruiting

Location contact

Alissa D'Gama, MD, PhD

PRINCIPAL_INVESTIGATOR

D'Gama Lab

CONTACT

[email protected]

617-355-5254

About this study

Neonatal encephalopathy (NE) is a disorder of term newborns involving dysfunction of the central nervous system and can impact one's health throughout the lifespan. While NE can be caused by a number of exposures or external factors, in some cases there is no cause identified or the severity of the condition cannot fully be explained by external factors. In these cases, there is increasing evidence to suggest underlying genetic factors may contribute to NE.

The investigators' research effort is focused on identifying genetic changes (known as "DNA variants") that cause or contribute to NE. By doing so the investigators hope to improve diagnosis and management of NE.

We have two specific aims:

Aim 1: To identify genetic causes of and contributors to NE and related disorders.

Aim 2: To correlate genetic findings with clinical features.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Proband Criteria:

Inclusion criteria

  • Diagnosed with neonatal encephalopathy during the neonatal period as documented in the electronic medical record
  • Less than 6 years old at the time of study enrollment
  • Patient at Boston Children's Hospital

Exclusion criteria

  • Genetic cause of NE already identified
  • Deceased prior to enrollment

Parent criteria:

Inclusion criteria

  • Biological parent of eligible proband (see above)

Treatment and study plan

Primary outcomes

  1. Diagnostic yield

    Time frame: 10 years

    The diagnostic yield of genomic sequencing will be calculated as the percentage of enrolled participants with NE who receive a genetic diagnosis.

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2035
Study completion
2035
First posted
Sep 10, 2025
Registry last updated
Mar 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.